CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

Neurology

Volumn 86, Issue 4, 2016, Pages 375-381

  Lieberman, Linda A ^a   Zeng, Wanyong ^a   Singh, Carol ^a   Wang, Wenting ^a   Otipoby, Kevin L ^a   Loh, Christine ^a   Plavina, Tatiana ^a   Gorelik, Leonid ^a   Ransohoff, Richard M ^a   Cahir Mcfarland, Ellen ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; L SELECTIN; NATALIZUMAB; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; BLOOD; BLOOD STORAGE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK; RISK ASSESSMENT;

ADULT; BIOMARKERS; BLOOD PRESERVATION; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CRYOPRESERVATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT;

EID: 84956716000     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002314     Document Type: Article

References (10)

1. Yaldizli O, Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2009; 2: 115-128.
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
3. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. Lselectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865-871.
4. O'Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014; 83: 78-86.
5. Kister I, Kuesters G, Chamot E, et al. IV immunoglobulin confounds JC virus antibody serostatus determination. Neurol Neuroimmunol Neuroinflamm 2014; 1: e29.
6. Weinberg A, Song LY, Wilkening C, et al. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol 2009; 16: 1176-1186.
7. Feuerecker M, Kaufmann I, Salam AP, Chouker A. Effects of cryopreservation with polyethylene glycol on the expression of CD11b and CD62L on the surface of polymorphonuclear leukocytes. Cryo Letters 2012; 33: 151-160.
8. Feuerecker M, Feuerecker B, Matzel S, et al. Five days of head-down-tilt bed rest induces noninflammatory shedding of L-selectin. J Appl Physiol 2013; 115: 235-242.
9. Herrera-Garcia A, Dominguez-Luis M, Arce-Franco M, et al. In vivo modulation of the inflammatory response by nonsteroidal antiinflammatory drug-related compounds that trigger L-selectin shedding. Eur J Immunol 2013; 43: 55-64.
10. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014; 1: 755-764.